Prostate Cancer

Dr Neeraj Agarwal on PARP Inhibitor Combination Treatments for Prostate Cancer

December 15th 2020, 9:00pm


Neeraj Agarwal, MD, a clinician and researcher at the University of Utah Huntsman Cancer Institute, discusses investigational combinations with PARP inhibitors in prostate cancer treatment.

Research Finds 2 New Targets for Prostate Cancer Therapies

December 12th 2020, 4:00pm


The genes are part of the family that cause cancer cells to grow.

Dr Neeraj Agarwal Discusses PARP Inhibitors as First-Line Prostate Cancer Treatment

December 11th 2020, 3:30pm


Neeraj Agarwal, MD, of the University of Utah's Huntsman Cancer Institute, discusses ongoing trials of PARP inhibitors as first-line metastatic prostate cancer treatments.

Prostate Cancer Cohort Shows Where Active Surveillance Presents Lowest Risk

December 5th 2020, 11:15pm


Researchers from the University of California San Francisco published their results in the Journal of Urology.

Dr Neeraj Agarwal on Why PARP Inhibitor Approval in Prostate Cancer Is Slow-Moving

December 2nd 2020, 9:30pm


Neeraj Agarwal, MD, of the University of Utah's Huntsman Cancer Institute, discusses challenges to progress in getting FDA approval for PARP inhibitors in prostate cancer.

African American Men Face Higher Risk of Aggressive Prostate Cancer, but Not Necessarily Death

November 26th 2020, 6:30pm


Multiple studies have suggested African American men tend to have more aggressive forms of prostate cancer, but a new study suggests that may not translate to a higher risk of death.

Genetic Signature Could Predict Prostate Cancer Metastasis

November 24th 2020, 3:00pm


The discovery of a genetic signature that correlates with metastasis in prostate cancer could make it much easier for physicians and patients to choose treatment strategies.

Commentary Examines What Is Known About BRCA1 Mutations Compared With BRCA2 in Prostate Cancer

November 21st 2020, 4:10pm


Authors in the Journal of Clinical Oncology discuss hypotheses on the differences in mutations and implications for treatment with PARP inhibitors.

Is a Brighter Future Possible for PARP Inhibitor Use in Prostate Cancer?

November 20th 2020, 9:48pm


Mounting evidence is supporting the use of poly ADP-ribose polymerase (PARP) inhibitors in prostate cancer, according to a new study.

Olaparib Cuts Risk of Death 31% in BRCA 1/2 or ATM-Mutated Metastatic Castration-Resistant Prostate Cancer

September 21st 2020, 2:16pm


Having biomarker-driven solutions in prostate cancer is important, because they have been lacking.